Table 2.
Region of Chromosome | NSCLC with mutant EGFR (n=8) | NSCLC from TCGA data base (n=56) | Potential target gene(s) |
---|---|---|---|
Gain of 1p36.32-36.31 |
8/9(89) |
15/56(27%) |
AJAP1 |
Gain of Ch2p |
Fewer alteration |
More alterations |
Large fragment |
Gain of Ch3q |
Fewer alteration |
More alterations |
Large fragment |
Loss of 6q22.3-27 |
Fewer alteration |
More alterations |
Large fragment |
Loss of 9p21.3 |
1/9(11%) |
19/56(34%) |
p14,p15,p16 |
Gain of 15q23-26.3 |
0/9(0%) |
10/56(18%) |
Large fragment |
Gain of 19q12 |
6/9(70%) |
6/56(11%) |
Cyclin E1 |
Gain of 20q11.21 | 0/9(0%) | 26/56(46%) | BCL2L1, TPX2, MYLK2, DUSP15 |
Ratio of genomic alterations in NSCLC samples with EGFR mutations (9 samples) and 56 NSCLC samples from the TCGA data base. [Most samples from TCGA are from Caucasians and thus we assume <7% will have EGFR mutation as previously noted (Zhou et al. [14])].